Pleiotropic platelet defects in mice with disrupted FOG1-NuRD interaction

Blood

Volumn 118, Issue 23, 2011, Pages 6183-6191

  Wang, Yuhuan ^a   Meng, Ronghua ^b   Hayes, Vincent ^a   Fuentes, Rudy ^a   Yu, Xiang ^a   Abrams, Charles S ^b   Heijnen, Harry F G ^c   Blobel, Gerd A ^a,b   Marks, Michael S ^b   Poncz, Mortimer ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FOG1 PROTEIN; HISTONE DEACETYLASE; PROTEIN; PROTEIN KINASE B; THROMBIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ERYTHROID CELL; GRAY PLATELET SYNDROME; LYSOSOME; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLEIOTROPY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; THROMBOCYTE AGGREGATION; THROMBOCYTE ANOMALY; THROMBOCYTOPENIA;

EID: 83055179245     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-363580     Document Type: Article

References (48)

1. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol. 2006;134(5):453-466. (Pubitemid 44141711)
2. Ferreira R, Ohneda K, Yamamoto M, Philipsen S. GATA1 function, a paradigm for transcription factors in hematopoiesis. Mol Cell Biol. 2005;25(4):1215- 1227. (Pubitemid 40204902)
3. Nichols KE, Crispino JD, Poncz M, et al. Familial dyserythropoietic anaemia and thrombocytopenia due to an inherited mutation in GATA1. Nat Genet. 2000;24(3):266-270. (Pubitemid 30132195)
4. Mehaffey MG, Newton AL, Gandhi MJ, Crossley M, Drachman JG. X-linked thrombocytopenia caused by a novel mutation of GATA-1. Blood. 2001;98(9):2681-2688.
5. Freson K, Devriendt K, Matthijs G, et al. Platelet characteristics in patients with X-linked macrothrombocytopenia because of a novel GATA1 mutation. Blood. 2001;98(1):85-92.
6. Freson K, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002(2):11:147-152.
7. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia due to a mutation in the amino finger of GATA-1 affecting DNA-binding rather than FOG-1 interaction. Blood. 2002;100(7):2040-2045. (Pubitemid 35001235)
8. Phillips JD, Steensma DP, Pulsipher MA, Spangrude GJ, Kushner JP. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood. 2007;109(6):2618-2621. (Pubitemid 46425911)
9. Tubman VN, Levine JE, Campagna DR, et al. X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood. 2007;109(8):3297-3299. (Pubitemid 46572516)
10. White JG, Nichols WL, Steensma DP. Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia I ultrastructure. Platelets. 2007;18(4):273-283. (Pubitemid 46854821)
11. White JG, Burris SM. Cytoskeletons of X-linked GATA-1, G208S macrothrombocytes are deficient in talin. Platelets. 2008;19(7):543-550.
12. Hong W, Nakazawa M, Chen YY, et al. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO J. 2005;24(13):2367-2378. (Pubitemid 41032588)
13. Miccio A, Wang Y, Hong W, et al. NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J. 2010;29(2):442-456.
14. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93(8):2867-2875. (Pubitemid 29200777)
15. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat. Genet. 2011;43(8):732-734.
16. Kahr WHA, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat. Genet. 2011;43(8):738-740.
17. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat. Genet. 2011;43(8):735-737.
18. Pang L, Xue HH, Szalai G, et al. Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood. 2006;108(7):2198-2206. (Pubitemid 44497500)
19. Sitaram A, Piccirillo R, Palmisano I, et al. Localization to mature melanosomes by virtue of cytoplasmic dileucine motifs is required for human OCA2 function. Mol Biol Cell. 2009;20(5):1464-1477.
20. Sehgal S, Storrie B. Evidence that differential packaging of the major platelet granule proteins von Willebrand factor and fibrinogen can support their differential release. J Thromb Haemost. 2007;5(10):2009-2016. (Pubitemid 47450016)
21. Marks MS, Roche PA, van Donselaar E,Woodruff L, Peters PJ, Bonifacino JS. A lysosomal targeting signal in the cytoplasmic tail of the beta chain directs HLA-DM to the MHC class II compartments. J Cell Biol. 1995;131(2):351-369.
22. Pannerden HN, Haas FD, GeertsW, Posthuma G, Dijk SV, Heijnen HFG. The platelet interior revisited: electron tomography reveals tubular alphagranule subtypes. Blood. 2010;116(7):1147-1156.
23. Nieswandt B, Schulte V, Bergmeier W. Flow-cytometric analysis of mouse platelet function. Methods Mol. Biol. 2004;272(1):255-268.
24. Basani RB, Zhu H, Thornton MA, et al. Species differences in small molecule binding to alpha IIb beta 3 are the result of sequence differences in 2 loops of the alpha IIb beta propeller. Blood. 2009;113(4):902-910.
25. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem. 2004;279(6):4186-4195. (Pubitemid 38199005)
26. Yarovoi HV, Kufrin D, Eslin DE, et al. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood. 2003;102(12):4006-4013. (Pubitemid 37486982)
27. Deng DXF, Tsalenko A, Vailaya A, et al. Differences in vascular bed disease susceptibility reflect differences in gene expression response to atherogenic stimuli. Circ Res. 2006;98(2):200-208.
28. Katz SG, Williams A, Yang J, et al. Endothelial lineage-mediated loss of the GATA cofactor Friend of GATA 1 impairs cardiac development. Proc Natl Acad Sci U S A. 2003;100(24):14030-14035. (Pubitemid 37499185)
29. Johnston GI, Kurosky A, McEver RP. Structural and biosynthetic studies of the granule membrane protein, GMP-140, from human platelets and endothelial cells. J Biol Chem. 1989;264(3):1816-1823. (Pubitemid 19051029)
30. Daugherty BL, Straley KS, Sanders JM, et al. AP-3 adaptor functions in targeting P-selectin to secretory granules in endothelial cells. Traffic. 2001;2(6):406-413. (Pubitemid 32574007)
31. Chen JW, Cha Y, Yuksel KU, Gracy RW, August JT. Isolation and sequencing of a cDNA clone encoding lysosomal membrane glycoprotein mouse LAMP-1: sequence similarity to proteins bearing onco-differentiation antigens. J Biol Chem. 1988;263(18):8754-8758.
32. Kim S, Jin J, Kunapuli SP. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood. 2006;107(3):947-954. (Pubitemid 43156291)
33. Hughan SC, Senis Y, Best D, et al. Selective impairment of platelet activation to collagen in the absence of GATA1. Blood. 2005;105(11):4369-4376. (Pubitemid 40720783)
34. Mori K, Suzuki S, Akutsu Y, Ishikawa M, Sakai H. Gray platelet syndrome: relationship between morphological abnormality of the dense tubular system (DTS) and intracellular Ca++ mobilization in the platelet. Nippon Ketsueki Gakkai Zasshi. 1989;52(8):1534-1541. (Pubitemid 20115689)
35. Ren Q, Wimmer C, Chicka MC, et al. Munc13-4 is a limiting factor in the pathway required for platelet granule release and hemostasis. Blood. 2010;116(6):869-877.
36. Shirakawa R, Higashi T, Tabuchi A, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem. 2004;279(11):10730-10737. (Pubitemid 38372686)
37. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev. 2007;21(1):21-36. (Pubitemid 46097190)
38. Jantunen E, Hänninen A, Naukkarinen A, Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am J Hematol. 1994;46(1):218-224. (Pubitemid 24206748)
39. Flaumenhaft R. Filling a void in gray platelets. Blood. 2010;116(23):4738-4740.
40. Levy-Toledano S, Caen JP, Breton-Gorius J, et al. Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med. 1981;98(6):831-848. (Pubitemid 12253328)
41. Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med. 1984;143(3):261-287. (Pubitemid 15195597)
42. Nurden P, Jandrot-Perrus M, Combrié R, et al. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood. 2004;104(1):107-114. (Pubitemid 38879845)
43. Facon T, Goudemand J, Caron C et al. Simultaneous occurrence of grey platelet syndrome and idiopathic pulmonary fibrosis: a role for abnormal megakaryocytes in the pathogenesis of pulmonary fibrosis? Br J Haematol. 1990;74(4):542-543. (Pubitemid 20122762)
44. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101(11):4333-4341. (Pubitemid 36857797)
45. Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-175. (Pubitemid 29455388)
46. Jalagadugula G, Mao G, Kaur G, Goldfinger LE, Dhanasekaran DN, Rao AK. Regulation of platelet myosin light chain (MYL9) by RUNX1: implications for thrombocytopenia and platelet dysfunction in RUNX1 haplodeficiency. Blood. 2010;116(26):6037-6045.
47. Jalagadugula G, Mao G, Kaur G, Dhanasekaran DN, Rao AK. Platelet protein kinase C-theta deficiency with human RUNX1 mutation: PRKCQ is a transcriptional target of RUNX1. Arterioscler Thromb Vasc Biol. 2011;31(4):921-927.
48. Aneja K, Jalagadugula G, Mao G, Singh A, RaoAK. Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. J Thromb Haemost. 2011;9(2):383-391.